Casopitant

Casopitant
Clinical data
Other names	GW679769; GW-679769; (2R,4S)-4-(4-Acetylpiperazin-1-yl)-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide
ATC code	A04AD13 (WHO) ;
Identifiers
	IUPAC name (2S,4S)-4-(4-Acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-1-piperidinecarboxamide;
CAS Number	414910-27-3;
PubChem CID	23725089;
ChemSpider	25069049;
UNII	3B03KPM27L;
KEGG	D06574;
ChEMBL	ChEMBL2107320;
CompTox Dashboard (EPA)	DTXSID40961762 ;
Chemical and physical data
Formula	C30H35F7N4O2
Molar mass	616.625 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC(=C1)F)[C@@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C;
	InChI InChI=1S/C30H35F7N4O2/c1-18-13-24(31)5-6-26(18)27-17-25(40-11-9-39(10-12-40)20(3)42)7-8-41(27)28(43)38(4)19(2)21-14-22(29(32,33)34)16-23(15-21)30(35,36)37/h5-6,13-16,19,25,27H,7-12,17H2,1-4H3/t19-,25-,27+/m1/s1; Key:XGGTZCKQRWXCHW-JRLVAEJTSA-N;
	(verify)

Casopitant (INNTooltip International Nonproprietary Name),^[1]^: 208 former tentative trade names Rezonic (U.S.) and Zunrisa (Europe), is an NK₁ receptor antagonist which was undergoing research for the treatment of chemotherapy-induced nausea and vomiting.^[2]^[3] It was under development by GlaxoSmithKline.^[2] In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn and development was discontinued in September 2009 because GlaxoSmithKline decided that further safety assessment was necessary.^[2]^[4] However, a 2022 review listed casopitant as under development as a potential novel antidepressant for the treatment of major depressive disorder, with a phase 2 clinical trial having been completed.^[5]